Health Enhancement Products Announces Commencement of Bovine Mastitis Testing With Contract Research Organization Dairy Experts
April 24 2014 - 7:23AM
Marketwired
Health Enhancement Products Announces Commencement of Bovine
Mastitis Testing With Contract Research Organization Dairy Experts
KEEGO HARBOR, MI--(Marketwired - Apr 24, 2014) - Health
Enhancement Products, Inc. (OTCBB: HEPI), a Michigan-based biotech
firm investigating bioactive compounds extracted from algal
cultures, is pleased to announce the kickoff of a large-scale
bovine study to gauge the efficacy of its candidate compounds in
addressing mastitis, a condition that affects the health of dairy
cows and impacts milk production. Mastitis affects up to 10% of the
US dairy herd at any given time and is responsible for nearly $3
billion in lost milk production annually. The US dairy herd numbers
9 million, about 3% of the world's entire population of 244 million
dairy cows. Mastitis is a global animal health problem.
Contract research organization Dairy Experts, sited in Tulare
County, California, will be conducting the study on behalf of the
Company. The firm conducts large-scale clinical studies for a
variety of institutions, both public and private.
The study is a requirement of an agreement in which Health
Enhancement Products, Inc. granted to Zoetis Inc., a global animal
health company based in Florham Park, New Jersey, an option for
future potential collaboration.
Extensive planning and study design, along with sourcing the
study itself, has consumed the better part of eight weeks and
culminated in tapping California-based Dairy Experts for the field
study. The study is complex and far-reaching. The scale of the
study is such that study groups will need to be staggered to
accommodate the anticipated logistical demands. Of specific
interest and focus is the effect of the Company's bioactives on
mycoplasma bovis, an untreatable pathogen that is
extremely contagious, irreversible in its pathology and present in
dairy herds across the country, with particular concentration in
California.
"This is a significant undertaking with a considerable number of
factors to control and observe," states Amy Steffek, Ph.D., Health
Enhancement Director of Research & Development. "We have three
of our research partners involved in a coordinated effort to
produce one set of test samples within a complex
extraction/purification process, while we work through a parallel
synthetic program to render active compounds in sufficient volume
for testing."
The Company expects to report a subset of preliminary results in
May.
About Dairy Experts
Dairy Experts is a contract research organization sited in
California, with a specific focus on clinical research to study
efficacy and safety of antibiotics, vaccines, teat dips, hoof
baths, feed additives, colostrum replacers and supplements for
dairy cows. Dairy Experts also provides contract research services
such as protocol development and implementation, research
laboratory studies, data management, statistical analyses and
reporting.
About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (OTCBB: HEPI) is a
Michigan-based biotech company engaged in the investigation of the
health benefits of bioactive compounds derived from its proprietary
algal cultures, and the development of natural bioactive compounds
for use as dietary supplements and food ingredients, as well as
biologics and synthetic candidates for medicinal and pharmaceutical
applications in humans and animals, specifically focused on
autoimmune modulation.
Safe Harbor Statement
Except for any historical information, the matters discussed in
this press release contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These forward-looking
statements involve risks and uncertainties. A number of factors
could cause actual results to differ from those indicated in the
forward-looking statements, including the timing of completion of a
trial, actual future clinical trial results being different than
the results the company has obtained to date, and the company's
ability to secure funding. Such statements are subject to a number
of assumptions, risks and uncertainties. Readers are cautioned that
such statements are not guarantees of future performance and those
actual results or developments may differ materially from those set
forth in the forward-looking statements. The company undertakes no
obligation to publicly update or revise forward-looking statements,
whether as a result of new information or otherwise.
Zivo Bioscience (QB) (USOTC:ZIVO)
Historical Stock Chart
From Apr 2024 to May 2024
Zivo Bioscience (QB) (USOTC:ZIVO)
Historical Stock Chart
From May 2023 to May 2024